Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits.

Atherosclerosis

Pharmacology, Lead Optimization, Drug Innovation and Approval Division, Aventis Pharma Ltd., 1-3-2 Minamidai, Kawagoe, Saitama 350-1165, Japan.

Published: October 2005

Aims/hypothesis: The purpose of this study was to examine the potential prophylactic effect of glimepiride on experimental atherosclerosis in rabbits and to elucidate the mechanism of action.

Methods: Rabbits were fed an atherogenic diet containing 1% cholesterol and glimepiride 0.1mg/kg/day for 10 weeks. Plasma lipid levels were determined every 2 weeks. The percentage of atherogenic lesions of thoracic aorta stained with oil red O was calculated and histological examination of the lesions was performed. Lipid and lipid peroxide contents in thoracic aorta and liver were also determined. In addition, the inhibitory effect of glimepiride on human coronary arterial endothelial cell-mediated LDL oxidation was evaluated.

Results: Accumulation of lipid-laden foam cells in the focal areas of arterial intima was observed in oil red O-positive atherosclerotic lesions. Glimepiride treatment produced significant reduction of atherosclerotic lesions (control, 57.5+/-7.1% versus glimepiride, 20.6+/-4.8%; P<0.01) with no significant change observed in levels of plasma lipids. There were marked decreases in lipid and lipid peroxide contents in the thoracic aorta in glimepiride-treated rabbits with no significant change in levels of liver lipids. In cultured human coronary arterial endothelial cells, glimepiride inhibited oxidative modification of LDL in a dose-dependent manner (IC(50)=8.8 x 10(-7)M) without cytotoxicity.

Conclusions/interpretation: These findings suggest that glimepiride prevents the development of aortic atherosclerosis in fat-fed rabbits. The underlying mechanism may be inhibition of endothelial cell-mediated LDL oxidation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosis.2005.01.044DOI Listing

Publication Analysis

Top Keywords

thoracic aorta
8
oil red
8
atherosclerotic lesions
8
glimepiride
6
glimepiride exhibits
4
exhibits prophylactic
4
prophylactic atherosclerosis
4
atherosclerosis cholesterol-fed
4
cholesterol-fed rabbits
4
rabbits aims/hypothesis
4

Similar Publications

Objective: Paravisceral aortic lesions present significant challenges for endovascular treatment. This retrospective analysis of consecutively treated patients from April 2017 to June 2021 aimed to analyse the outcome of primary intra-operative embolisation of aortic complicated pseudoaneurysms and gutter channels during parallel graft (PG) repair of paravisceral symptomatic aortic pseudoaneurysms.

Methods: Patients with symptomatic pseudoaneurysms of the paravisceral aorta treated with PGs using chimney or periscope configurations were included.

View Article and Find Full Text PDF

Chronic mesenteric ischemia (CMI) is a progressive condition that primarily affects the elderly, causing chronic abdominal pain and malnutrition. Timely treatment is essential to prevent further deconditioning or bowel ischemia. Surgical repair options include both endovascular and open procedures.

View Article and Find Full Text PDF

Perforation of the duodenum after trauma has a low incidence and its coincidence with BTAI is very rare. The clinical condition of the patient is very important for deciding the treatment priority. In this patient, considering the stable condition and degree of aorta injury, we chose TEVAR before laparotomy.

View Article and Find Full Text PDF

Transcriptome analysis of the aortic coarctation area.

J Mol Cell Cardiol Plus

December 2024

Department of Clinical Genetics, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

Background: Coarctation of the aorta (CoA) is a relatively common congenital heart defect. The underlying causes are not known, but a combination of genetic factors and abnormalities linked to embryonic development is suspected. There are only a few studies of the underlying molecular mechanisms in CoA.

View Article and Find Full Text PDF

Background: Although alloimmunization risk of pathogen-reduced (PR) platelets has been studied, the risk has not been reported with PR red blood cells (RBCs).

Study Design And Methods: In a Phase III, randomized, controlled trial (Red Cell Pathogen Inactivation), cardiac or thoracic-aorta surgery patients were randomized to transfusion with amustaline/glutathione PR versus conventional RBCs. Pre-transfusion and Day 28 samples were evaluated for Human leukocyte antigen (HLA) Class I and Class II antibodies at low, medium, and high cutoff values.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!